Letter from FDA on Colcrys®
April 02, 2010
Many ACR members have reached out to the Food and Drug Administration to express concern over the drastic increase in price for colchicine. In response to these communications regarding, Janet Woodcock, MD, Director of Center for Drug Evaluation and Research has responded explaining FDA’s decision to regulate unapproved products such as colchicine and highlights the approval process URL Pharma, Inc. took for Colcrys®.
